VALBIOTIS (EPA:ALVAL) | WebDisclosure

Basculer en Français

9865	Companies
198267	Keywords
129311	Articles
105440	Press releases

Home
Companies
VALBIOTIS

PRESS RELEASE

published on 01/21/2025 at 17:40, 1 year ago

VALBIOTIS SA: Valbiotis dévoile ses ambitions stratégiques et financières à horizon 2030
Valbiotis dévoile ses ambitions stratégiques et financières à horizon 2030 avec trois produits pour la prise en charge des troubles cardio-métaboliques sur le marché en France dès 2025

Commercialisation Valbiotis Ambitions Stratégiques Financières Cardio-métaboliques
BRIEF

published on 01/14/2025 at 17:49, 1 year 1 month ago

Valbiotis Announces Success in HEART II Study on Lipidrive

Valbiotis Lipidrive Hypercholesterolemia HEART II Study LDL Cholesterol
BRIEF

published on 01/14/2025 at 17:49, 1 year 1 month ago

Valbiotis annonce le succès de l'étude HEART II sur Lipidrive

Valbiotis Cholestérol LDL Hypercholestérolémie Lipidrive Étude HEART II
PRESS RELEASE

published on 01/14/2025 at 17:45, 1 year 1 month ago

VALBIOTIS SA: Valbiotis annonce le large succès de l’étude clinique de phase II/III HEART II sur LIPIDRIVE
Valbiotis annonce le succès de l'étude clinique de phase II/III HEART II sur Lipidrive. Efficacité prouvée sur la réduction du LDL Cholestérol chez individus avec hypercholestérolémie légère à modérée

Valbiotis Étude Clinique Santé Cardiovasculaire Hypercholestérolémie LDL Cholesterol
PRESS RELEASE

published on 01/14/2025 at 17:44, 1 year 1 month ago

VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Valbiotis announces success of phase II/III HEART II study on LIPIDRIVE, proving efficacy in reducing LDL cholesterol for mild to moderate hypercholesterolemia. Study validates safety & compliance of Lipidrive

Valbiotis Lipidrive Hypercholesterolemia HEART II Study LDL Cholesterol
PRESS RELEASE

published on 01/14/2025 at 17:44, 1 year 1 month ago

VALBIOTIS SA: Valbiotis annonce le large succès de l’étude clinique de phase II/III HEART II sur LIPIDRIVE
Valbiotis annonce le large succès de l'étude clinique de phase II/III HEART II sur LIPIDRIVE, démontrant l'efficacité sur la réduction du LDL Cholestérol. L'étude confirme l'approche scientifique innovante de Valbiotis

Valbiotis Santé Efficacité Étude Clinique LDL Cholesterol
BRIEF

published on 01/08/2025 at 12:02, 1 year 1 month ago

Bilan semestriel du contrat de liquidité de Valbiotis

Contrat De Liquidité PORTZAMPARC Bourse Valbiotis Transactions Boursières
BRIEF

published on 01/08/2025 at 12:02, 1 year 1 month ago

Half-yearly report on the Valbiotis liquidity contract

Liquidity Contract PORTZAMPARC Valbiotis Sotck Exchange Stock Market Transactions
PRESS RELEASE

published on 01/08/2025 at 11:57, 1 year 1 month ago

VALBIOTIS SA: Bilan semestriel du contrat de liquidité
Valbiotis SA présente le bilan semestriel de son contrat de liquidité confié à Portzamparc. Détails des moyens et des transactions effectuées

Contrat De Liquidité Bilan Semestriel Transactions PORTZAMPARC Valbiotis SA
BRIEF

published on 12/17/2024 at 11:19, 1 year 1 month ago

VALBIOTIS : Information Mensuelle sur les Droits de Vote et Actions

Euronext Growth Paris Droits De Vote Franchissement De Seuil Actions Valbiotis

Accesswire

Published on 02/14/2026 at 01:00, 17 hours 46 minutes ago

Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:30, 20 hours 16 minutes ago

Norse Gold Corp. Announces New Director
Published on 02/13/2026 at 22:15, 20 hours 31 minutes ago

Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 1 day 1 hour ago

Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 1 day 4 hours ago

Datametrex Received $500,000 Purchase Order For Data Centre Solutions

View all ACCESSWIRE

EQS Group

Published on 02/14/2026 at 16:30, 2 hours 15 minutes ago

Milano Cortina 2026 Licensed Candies Released Globally
Published on 02/14/2026 at 06:05, 12 hours 40 minutes ago

The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 23 hours 25 minutes ago

Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 23 hours 44 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 1 day ago

GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE

Les Echos

Published on 02/14/2026 at 07:00, 11 hours 46 minutes ago

Groupe DLSI - Chiffre d'affaires 2025
Published on 02/13/2026 at 18:05, 1 day ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 1 day ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 1 day ago

Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 1 day ago

Nombre total d'actions et droits de vote - janvier 2026

View all LES ECHOS COMFI WIRE